bisphosphonate-associated osteonecrosis of the jaw

bisphosphonate-associated osteonecrosis of the jaw (BON),

References in periodicals archive ?
INTRODUCTION: Bisphosphonate-associated osteonecrosis of the jaw, often abbreviated as BON, BON of the jaw or even BRONJ, is a recently discovered dental phenomenon that may lead to surgical complication in the form of impaired wound healing following oral or periodontal surgery or endodontic therapy.
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Bisphosphonate-associated osteonecrosis of the jaw (BON) is defined as the unexpected development of necrotic bone in the oral cavity of a patient who is receiving bisphosphonate treatment and has not received radiotherapy to the head and neck.
Bisphosphonate-associated osteonecrosis of the jaw represents a serious side effect of bisphosphonate administration.
Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the patient has undergone dental surgery.
Canadian consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw.
In 2003, dentists started to see patients with a serious bone disease, bisphosphonate-associated osteonecrosis of the jaw (BON).
As the discussions of the association between BIS drug therapy and ONJ have emerged, another anachronism has been proposed, namely bisphosphonate-associated osteonecrosis of the jaw (BON).
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.